Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
A favorable patent-infringement ruling on September 30 adds a recent catalyst to an 11.9% 21-day share gain. Strong liquidity, positive free cash flow and no debt support the case, despite an October 2 pullback.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Zero Debt ⢠Strong Liquidity ⢠Margin Moderation UTHR is financially strong with exceptional margins, cash generation, liquidity, and zero debt, but recent margin moderation, lower equity, and no dividend warrant a balanced stance.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Weak momentum Support Level: $487.61â$490.24 Resistance Level: $500â$504 UTHR is bearish over the last month, with support at $487.61â$490.24 and a recovery requiring a sustained move above $500â$504.
Sentiment & News
Key News Insights: ⢠FDA Application Progress ⢠Accelerated Buyback ⢠Mixed Trading Signals United Therapeutics' FDA filings and buyback strengthen its growth outlook, though recent share weakness, insider sales, and mixed institutional activity warrant caution.
AI Summary
UTHR is a financially durable but increasingly execution-dependent investment: its debt-free, cash-generative Tyvaso franchise funds major upside from IPF Tyvaso and ralinepag, yet slowing core revenue and heavier spending mean the thesis now hinges on successful 2027 FDA approvals and commercialization rather than legacy growth. Investors should view current weakness as an opportunity only if they can tolerate binary regulatory risk and potential margin pressure ahead of those catalysts.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and lifeâthreatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclinâbased treatments for pulmonary arterial hypertension and an antibody therapy for highârisk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 2 | Oct 9 | UTHR | United Therapeutics Corporation | A favorable patent-infringement ruling on September 30 adds a recent catalyst to an 11.9% 21-day share gain. Strong liquidity, positive free cash flow and no debt support the case, despite an October 2 pullback. | Closed | +1.4% |
| Mar 31 | Apr 7 | UTHR | United Therapeutics Corporation | Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETONâ1 Tyvaso data) plus a justâlaunched $2.0B buyback with a $1.5B ASR executed on 2026â03â09 and strong FY2025 revenue/FCF have driven a +16.9% 21âday ROC and price ~10% above its 21âday SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions. | Closed | -4.6% |
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong nearâterm setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETONâ2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into midâMarch. Combination of active repurchases, deârisked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Closed | -2.2% |